Risk factors related to the development and mortality from invasive cervical cancer: Clinical utility and impact on prevention

Obstetrics and Gynecology Clinics of North America

Volumn 29, Issue 4, 2002, Pages 817-842

  Lonky, Neal M ^a,b  

^a Kaiser Permanente ^*  (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ORAL CONTRACEPTIVE AGENT;

CANCER MORTALITY; CANCER SCREENING; FEMALE; GENETIC PREDISPOSITION; HEALTH BEHAVIOR; HEALTH CARE ACCESS; HUMAN; LIFE CYCLE; MALIGNANT TRANSFORMATION; NUTRITION; OPEN READING FRAME; OUTCOMES RESEARCH; PAPANICOLAOU TEST; PATIENT CARE; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SEXUAL BEHAVIOR; SEXUALLY TRANSMITTED DISEASE; SMOKING; UTERINE CERVIX CANCER; UTERINE CERVIX DYSPLASIA; WART VIRUS;

FEMALE; HUMANS; MASS SCREENING; NEOPLASM INVASIVENESS; RISK FACTORS; TUMOR MARKERS, BIOLOGICAL; UNITED STATES; UTERINE CERVICAL NEOPLASMS;

EID: 0036925022     PISSN: 08898545     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0889-8545(02)00021-9     Document Type: Review

References (115)

1. Anttila A, Pukkala E, Soderman B, et al. Effect of organised screening on cervical cancer incidence and mortality in Finland, 1963-1995: Recent increase in cervical cancer incidence. Int J Cancer 1999;83:59-65.
2. Christopherson WM, Lundin FE, Mendez WM. Cervical cancer control: A study of morbidity and mortality trends over a twenty-one year period. Cancer 1976;38:1357-66.
3. Laara E, Day NE, Hakama M. Trends in mortality from cervical cancer in the Nordic countries: Association with organised screening programmes. Lancet 1987;1:1247-9.
4. Dickinson L, Mussey ME, Kurland LT. Evaluation of the effectiveness of cytologic screening for cervical cancer. II. Survival parameters before and after the inception of screening. Mayo Clin Proc 1972;47:545-9.
5. Richart RM. Screening. The next century. Cancer 1995;76:1919-27.
6. Agency for Health Care Policy and Research. Evaluation of Cervical Cytology: Evidence Report/Technology Assessment, No. 5. (AHCPR99-E0110), March 1999.
7. Lonky NM. Overview of cervical cancer screening: The present standard of care. In: Morrow T, editor. Managed Care Consultant. Proceedings of Conference "The Future of Cervical Cancer Diagnostics," in Atlanta, GA, in 2002. Millstone, NJ: Princeton Associates; 2002. p. 5-9.
8. Mannino J. Colposcopy in the routine pelvic examination: Reducing the false-negative rate in annual cervical cancer screening. The Female Patient 1991;16:26-34.
9. Pete I, Toth V, Bosze P. The value of colposcopy in screening cervical carcinoma. Eur J Gynaecol Oncol 1998;19:120-2.
10. Guerra B, De Simone P, Gabrielli S, et al. Combined cytology and colposcopy to screen for cervical cancer in pregnancy. J Reprod Med 1998;43:647-53.
11. Schiffman M, Herrero R, Hildesheim A, et al. HPV DNA testing in cervical cancer screening: Results from women in a high-risk province of Costa Rica. JAMA 2000;283:87-93.
12. Paavonen J, Stevens CE, Wolner-Hanssen P, et al. Colposcopic manifestations of cervical and vaginal infections. Obstet Gynecol Surv 1988;43:373-81.
13. Lonky NM. Perspectives in cervical cancer prevention and health services management. J Lower Genital Tract Dis 1999;3:122-30.
14. Coppleson M, Reid B, Skladnev V, et al. An electronic approach to the detection of pre-cancer and cancer of the uterine cervix: A preliminary evaluation of Polarprobe. Int J Gynecol Cancer 1994;4:79-83.
15. Lonky NM, Sadeghi M, Tsadik GW, et al. The clinical significance of the poor correlation of cervical dysplasia and cervical malignancy with referral cytologic results. Am J Obstet Gynecol 1999;181:560-6.
16. Wertlake P, Francus K, Newkirk G, et al. Effectiveness of the Papanicolaou smear and speculoscopy as compared with the Papanicolaou smear alone: A community-based clinical trial. Obstet Gynecol 1997;90:421-7.
17. van Niekerk WA, Dunton CJ, Richart RM, et al. Colposcopy, cervicography, speculoscopy and endoscopy. International Academy of Cytology Task Force summary. Diagnostic cytology towards the 21st century: An international expert conference and tutorial. Acta Cytol 1998;42:33-49.
18. Sevin BU. Social implications of sexually transmitted cancer. J Womens Health Gend Based Med 1999;8:759-66.
19. Nobbenhuis MA, Meijer CJ, van den Brule AJ, et al. Addition of high-risk HPV testing improves the current guidelines on follow-up after treatment for cervical intraepithelial neoplasia. Br J Cancer 2001;84:796-801.
20. Wright TC, Kurman RJ, Ferenczy A. Precancerous lesions of the cervix. In: Blaustein's Pathology of the Female Genital Tract. 5th Edition. New York, NY: Springer-Verlag; p. 253-324.
21. Wright TC, Kurman RJ, Ferenczy A. Precancerous lesions of the cervix. In: Kurman RJ, editor. Blaustein's Pathology of the Female Genital Tract. 5th Edition. New York, NY: Springer-Verlag; 2001. p. 253-324.
22. Lorincz AT, Reid R, Jenson AB, et al. Human papillomavirus infection of the cervix: Relative risk associations of 15 common anogenital types. Obstet Gynecol 1992;79:328-37.
23. Chichareon S, Herrero R, Munoz N, et al. Risk factors for cervical cancer in Thailand: A casecontrol study. J Natl Cancer Inst 1998;90:50-7.
24. Jacobs MV, Snijders PJ, van den Brule AJ, et al. A general primer GP5+/GP6(+)-mediated PCR-enzyme immunoassay method for rapid detection of 14 high-risk and 6 low-risk human papillomavirus genotypes in cervical scrapings. J Clin Microbiol 1997;35:791-5.
25. Pfister H. The role of human papillomavirus in anogenital cancer. Obstet Gynecol Clin N Am 1996;23:579-95.
26. zur Hausen H. Papillomaviruses causing cancer: Evasion from host-cell control in early events in carcinogenesis. J Natl Cancer Inst 2000;92:690-8.
27. Bosch FX, Manos MM, Munoz N, et al. Prevalence of human papillomavirus in cervical cancer: A worldwide perspective. International biological study on cervical cancer (IBSCC) Study Group. J Natl Cancer Inst 1995;87:796-802.
28. Walboomers JM, Jacobs MV, Manos MM, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999;189:12-9.
29. Lambropoulos AF, Agorastos T, Frangoulides E, et al. Detection of human papillomavirus using the polymerase chain reaction and typing for HPV16 and 18 in the cervical smears of Greek women. J Med Virol 1994;43:228-30.
30. Wright Jr TC, Denny L, Kuhn L, et al. HPV DNA testing of self-collected vaginal samples compared with cytologic screening to detect cervical cancer. JAMA 2000;283:81-6.
31. Siritantikorn S, Laiwejpithaya S, Siripanyaphinyo U, et al. Detection and typing of human papilloma virus DNAs in normal cervix, intraepithelial neoplasia and cervical cancer in Bangkok. Southeast Asian J Trop Med Public Health 1997;28:707-10.
32. Cuzick J, Sasieni P, Davies P, et al. A systematic review of the role of human papilloma virus (HPV) testing within a cervical screening programme: Summary and conclusions. Br J Cancer 2000;83:561-5.
33. Koutsky LA, Holmes KK, Critchlow CW, et al. A cohort study of the risk of cervical intraepithelial neoplasia grade 2 or 3 in relation to papillomavirus infection. N Engl J Med 1992;327:1272-8.
34. Swan DC, Tucker RA, Tortolero-Luna G, et al. Human papillomavirus (HPV) DNA copy number is dependent on grade of cervical disease and HPV type. J Clin Microbiol 1999;37:1030-4.
35. Kyo S, Inoue M, Koyama M, et al. Detection of high-risk human papillomavirus in the cervix and semen of sex partners. J Infect Dis 1994;170:682-5.
36. Green J, Monteiro E, Bolton VN, et al. Detection of human papillomavirus DNA by PCR in semen from patients with and without penile warts. Genitourin Med 1991;67:207-10.
37. Solomon D, Schiffman M, Tarone R. Comparison of three management strategies for patients with atypical squamous cells of undetermined significance: Baseline results from a randomized trial. J Natl Cancer Inst 2001;93:293-9.
38. Broders AC. Carcinoma in situ contrasted with benign penetrating epithelium. JAMA 1932;99:1670-4.
39. Kolstad P, Klem V. Long-term follow up of 1121 cases of carcinoma in situ. Obstet Gynecol 1979;48:125-33.
40. Reagan JW, Ng APB, Wentz WB. Concepts of genesis and development in early cervical neoplasia. Obstetrican and Gynecological Survey 1969;24:860-74.
41. Crocker FJ, Fox H, Langley FA. Consistency in the histological diagnosis of epithelial abnormalities of the cervix uteri. J Clin Pathol 1968;21:67-70.
42. Richart RM. Cervical intraepithelial neoplasia. Pathol Annu 1973;8:301-28.
43. Fu YS, Reagan JW, Richart RM. Precursors of cervical cancer. Cancer Surv 1983;2:359-82.
44. NCI. National Cancer Institute Workshop: The 11988 Bethesda system for reporting cervical/vaginal cytologic diagnoses. JAMA 1988;262:931-4.
45. Rasbridge SA, Nayagam M. Discordance between cytologic and histologic reports in cervical intraepithelial neoplasia. Results of a one-year audit. Acta Cytol 1995;39:648-53.
46. Stoler MH, Schiffman M. Interobserver reproducibility of cervical cytologic and histologic interpretations: Realistic estimates from the ASCUS-LSIL Triage Study. JAMA 2001;285:1500-5.
47. Kashyap V, Das DK, Luthra UK. Microphotometric nuclear DNA analysis in cervical dysplasia of the uterine cervix: Its relation to the progression to malignancy and regression to normalcy. Neoplasma 1990;37:497-500.
48. Nasiell K, Roger V, Nasiell M. Behavior of mild cervical dysplasia during long-term follow-up. Obstet Gynecol 1986;67:665-9.
49. Follen-Mitchell M, Schottenfield D. The Natural History of Cervical Intraepithelial Neoplasia and the Management of Abnormal Papanicolaou Smears in Cervical Cancer and Preinvasive Neoplasia. Philadelphia, PA: Lipincott-Raven; 1996.
50. Montz FJ, Monk BJ, Fowler JM, et al. Natural history of the minimally abnormal Papanicolaou smear. Obstet Gynecol 1992;80:385-8.
51. Nash J, Burke T, Hoskins W. Biologic course of cervical human papillomavirus infection. Obstet Gynecol 1987;69:160-2.
52. Law KS, Chang TC, Hsueh S, et al. High prevalence of high grade squamous intraepithelial lesions and microinvasive carcinoma in women with a cytologic diagnosis of low grade squamous intraepithelial lesions. J Reprod Med 2001;46:61-4.
53. Massad LS, Halperin CJ, Bitterman P. Correlation between colposcopically directed biopsy and cervical loop excision. Gynecol Oncol 1996;60:400-3.
54. Buxton E, Luesley D, Shafi M, et al. Colposcopically directed punch biopsy: A potentially misleading investigation. Brit J Obstet Gynecol 1991;98:1273-6.
55. Felix JC, Lonky NM, Yu KJ, et al. Aberrant expression of E-cadherin in cervical intraepithelial neoplasia correlates with a false negative Papanicolaou smear. Am J Obstet Gynecol 2002;186:1308-14.
56. de Boer CJ, van Dorst E, van Krieken H, et al. Changing roles of cadherins and catenins during progression of squamous intraepithelial lesions in the uterine cervix. Am J Pathol 1999;155:505-15.
57. Vessey CJ, Wilding J, Folarin N, et al. Altered expression and function of E-cadherin in cervical intraepithelial neoplasia and invasive squamous cell carcinoma. J Pathol 1995;176:151-9.
58. Jarmulowicz MR, Jenkins D, Barton SE, et al. Cytological status and lesion size: A further dimension in cervical intraepithelial neoplasia. Br J Obstet Gynaecol 1989;96:1061-6.
59. Kierkegaard O, Byralsen C, Hansen KC, et al. Association between colposcopic findings and histology in cervical lesions: The significance of the size of the lesion. Gynecol Oncol 1995;57:66-71.
60. Sun CA, Lai HC, Chang CC, et al. The significance of human papillomavirus viral load in prediction of histologic severity and size of squamous intraepithelial lesions of uterine cervix. Gynecol Oncol 2001;83:95-9.
61. Raab SS, Bishop NS, Zaleski MS, Long-term outcome and relative risk in women with atypical squamous cells of undetermined significance. Am J Clin Pathol 1999;112:57-62.
62. Wright TC, Sun XW, Koulos J. Comparison of management algorithms for the evaluation of women with low-grade cytologic abnormalities. Obstet Gynecol 1995;85:202-10.
63. Vessey MP. Epidemiological studies of the effects of diethylstilboestrol. IARC Sci Publ 1989;96:335-48.
64. Cason J, Rice P, Best JM. Transmission of cervical cancer-associated human papilloma viruses from mother to child. Intervirology 1998;41:213-8.
65. Wang X, Zhu Q, Rao H. Maternal-fetal transmission of human papillomavirus. Chin Med J (Engl) 1998;111:726-7.
66. Singer A. The cervical epithelium during puberty and adolescence. In: Jordan JA, editor. The Cervix. London: WB Saunders; 1976. p. 87-104.
67. Mougin C, Dalstein V, Pretet JL, et al. Epidemiology of cervical papillomavirus infections. Recent knowledge. Presse Med 2001;30:1017-23.
68. Herrero R, Brinton LA, Reeves WC, et al. Sexual behavior, venereal diseases, hygiene practices, and invasive cervical cancer in a high-risk population. Cancer 1990;65:380-6.
69. Bosch FX, Munoz N, de Sanjose S, et al. Human papillomavirus and cervical intraepithelial neoplasia grade III/carcinoma in situ: A case-control study in Spain and Colombia. Cancer Epidemiol Biomarkers Prev 1993;2:415-22.
70. Miller BA, Kolonel LN, Bernstein L, et al. Racial/Ethnic Patterns of Cancer in the United States, 1988-1992. NIH Pub 96-4104. Bethesda, MD: National Cancer Institute; 1996.
71. Tortolero-Luna G, Mitchell MF, Swan DC, et al. A case-control study of human papillomavirus and cervical squamous intraepithelial lesions (SIL) in Harris County, Texas: Differences among racial/ethnic groups. Cad Saude Publica 1998;14(Suppl 3):149-59.
72. Phillips AN, Smith GD. Cigarette smoking as a potential cause of cervical cancer: Has confounding been controlled? Int J Epidemiol 1994;23:42-9.
73. Phillips DH, She MN. DNA adducts in cervical tissue of smokers and non-smokers. Mutat Res 1994;313:277-84.
74. Simons AM, Mugica van Herckenrode C, Rodriguez JA, et al. Demonstration of smokingrelated DNA damage in cervical epithelium and correlation with human papillomavirus type 16, using exfoliated cervical cells. Br J Cancer 1995;71:246-9.
75. Hellberg D, Nilsson S, Haley NJ, et al. Smoking and cervical intraepithelial neoplasia: Nicotine and cotinine in serum and cervical mucus in smokers and nonsmokers. Am J Obstet Gynecol 1988;158:910-3.
76. Brisson J, Morin C, Fortier M, et al. Risk factors for cervical intraepithelial neoplasia: Differences between low- and high-grade lesions. Am J Epidemiol 1994;140:700-10.
77. Brisson J, Roy M, Fortier M, et al. Condyloma and intraepithelial neoplasia of the uterine cervix: A case-control study. Am J Epidemiol 1988;128:337-42.
78. Kjellberg L, Hallmans G, Ahren AM, et al. Smoking, diet, pregnancy and oral contraceptive use as risk factors for cervical intra-epithelial neoplasia in relation to human papillomavirus infection. Br J Cancer 2000;82:1332-8.
79. Szarewski A, Jarvis MJ, Sasieni P, et al. Effect of smoking cessation on cervical lesion size. Lancet 1996;347:941-3.
80. Olsen AO, Dillner J, Gjoen K, et al. A population-based case-control study of human papillomavirus-type-16 seropositivity and incident high-grade dysplasia of the uterine cervix. Int J Cancer 1996;68:415-9.
81. Kjaer SK, Engholm G, Dahl C, et al. Case-control study of risk factors for cervical squamous cell neoplasia in Denmark. IV: Role of smoking habits. Eur J Cancer Prev 1996;5:359-65.
82. Halpert R, Fruchter RG, Sedlis A, et al. Human papillomavirus and lower genital neoplasia in renal transplant patients. Obstet Gynecol 1986;68:251-8.
83. Stanley MA. Human papillomavirus and cervical carcinogenesis. Best Pract Res Clin Obstet Gynaecol 2001;15:663-76.
84. Maiman M, Fruchter RG, Sedlis A, et al. Prevalence, risk factors, and accuracy of cytologic screening for cervical intraepithelial neoplasia in women with the human immunodeficiency virus. Gynecol Oncol 1998;68:233-9.
85. Chopra KF, Tyring SK. The impact of the human immunodeficiency virus on the human papillomavirus epidemic. Arch Dermatol 1997;133:629-33.
86. Maiman M. Management of cervical neoplasia in human immunodeficiency virus-infected women. J Natl Cancer Inst Monogr 1998;23:43-9.
87. Alloub MI, Barr BB, McLaren KM, et al. Human papillomavirus infection and cervical intraepithelial neoplasia in women with renal allografts. BMJ 1989;298:153-6.
88. Miller AB, Lindsay J, Hill GB. Mortality from cancer of the uterus in Canada and its relationship to screening for cancer of the cervix. Int J Cancer 1976;17:602-12.
89. La Vecchia C, Franceschi S, Decarli A, et al. "Pap" smear and the risk of cervical neoplasia: Quantitative estimates from a case-control study. Lancet 1984;2:779-82.
90. Brinton LA. Oral contraceptives and cervical neoplasia. Contraception 1991;43:581-95.
91. Negrini BP, Schiffman MH, Kurman RJ, et al. Oral contraceptive use, human papillomavirus infection,and risk of early cytological abnormalities of the cervix. Cancer Res 1990;50:4670-5.
92. Bosch FX, Munoz N, de Sanjose S, et al. Risk factors for cervical cancer in Colombia and Spain. Int J Cancer 1992;52:750-8.
93. Tabrizi SN, Fairley CK, Chen S, et al. Epidemiological characteristics of women with high grade CIN who do and do not have human papillomavirus. Br J Obstet Gynaecol 1999;106:252-7.
94. Nevin J, Soeters R, Dehaeck K, et al. Cervical carcinoma associated with pregnancy. Obstet Gynecol Surv 1995;50:228-39.
95. Herbst AL, Kurman RJ, Scully RE. Vaginal and cervical abnormalities after exposure to stilbestrol in utero. Obstet Gynecol 1972;40:287-98.
96. Furgyik S, Grubb R, Kullander S, et al. Familial occurrence of cervical cancer, stages 0-IV. Acta Obstet Gynecol Scand 1986;65:223-7.
97. Magnusson PK, Lichtenstein P, Gyllensten UB. Heritability of cervical tumours. Int J Cancer 2000;88:698-701.
98. Aoki K, Katahira T. Takagi T, et al. HLA and cervical carcinoma [author's translation]. Nippon Sanka Fujinka Gakkai Zasshi 1982;34:677-84.
99. Gostout BS, Podratz KC, McGovern RM, et al. Cervical cancer in older women: A molecular analysis of human papillomavirus types, HLA types, and p53 mutations. Am J Obstet Gynecol 1998;179:56-61.
100. Krul EJ, Schipper RF, Schreuder GM, et al. HLA and susceptibility to cervical neoplasia. Hum Immunol 1999;60:337-42.
101. DiPaolo JA, Woodworth CD, Coutlee F, et al. Relationship of stable integration of herpes simplex virus-2 Bg/II N subfragment Xho2 to malignant transformation of human papillomavirus-immortalized cervical keratinocytes. Int J Cancer 1998;76:865-71.
102. Hildesheim A, Mann V, Brinton LA, et al. Herpes simplex virus type 2: A possible interaction with human papillomavirus types 16/18 in the development of invasive cervical cancer. Int J Cancer 1991;49:335-40.
103. Koskela P, Anttila T, Bjorge T, et al. Chlamydia trachomatis infection as a risk factor for invasive cervical cancer. Int J Cancer 2000;85:35-9.
104. Smith JS, Munoz N, Herrero R, et al. Evidence for Chlamydia trachomatis as a human papillomavirus cofactor in the etiology of invasive cervical cancer in Brazil and the Philippines. J Infect Dis 2002;185:324-31.
105. de Sanjose S, Munoz N, Bosch FX, et al. Sexually transmitted agents and cervical neoplasia in Colombia and Spain. Int J Cancer 1994;56:358-63.
106. Potischman N, Brinton LA. Nutrition and cervical neoplasia. Cancer Causes Control 1996;7:113-26.
107. Goodman MT, Kiviat N, McDuffie K, et al. The association of plasma micronutrients with the risk of cervical dysplasia in Hawaii. Cancer Epidemiol Biomarkers Prev 1998;7:537-44.
108. Giuliano AR, Papenfuss M, Nour M, et al. Antioxidant nutrients: Associations with persistent human papillomavirus infection. Cancer Epidemiol Biomarkers Prev 1997;6:917-23.
109. Meyskens Jr FL, Manetta A. Prevention of cervical intraepithelial neoplasia and cervical cancer. Am J Clin Nutr 1995;62:1417S-9S.
110. Fowler BM, Giuliano AR, Piyathilake C, et al. Hypomethylation in cervical tissue: Is there a correlation with folate status? Cancer Epidemiol Biomarkers Prev 1998;7:901-6.
111. Butterworth Jr CE, Hatch KD, Macaluso M, et al. Folate deficiency and cervical dysplasia. JAMA 1992;267:528-33.
112. Weinstein SJ, Ziegler RG, Selhub J, et al. Elevated serum homocysteine levels and increased risk of invasive cervical cancer in US women. Cancer Causes Control 2001;12:317-24.
113. Holowaty P, Miller AB, Rohan T, et al. Natural history of dysplasia of the uterine cervix. J Natl Cancer Inst 1999;91:252-8.
114. Gail MH. The estimation and use of absolute risk for weighing the risks and benefits of selective estrogen receptor modulators for preventing breast cancer. Ann NY Acad Sci 2001;949:286-91.
115. Salih AK, Fentiman IS. Breast cancer prevention: Present and future. Cancer Treat Rev 2001;27:261-73.